Tibrintan Tablets 90 mg (Ticagrelor)

Adult dose

This medicine should not be used in combination with other ADP receptor inhibitors (ticlopidine, clopidogrel, prasugrel). Acute coronary syndrome: Administer an initial dose of 180mg, followed by 90mg twice daily. Treatment is recommended for 12 months unless discontinuation of this medicine is clinically necessary. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. Patients with a history of myocardial infarction (occurring at least 1 year previously) who are at high risk of thrombotic cardiovascular events: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. - Patients who took 90mg of this medicine or another ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel) during the first year after myocardial infarction may continue treatment with 60mg of this medicine. - This medicine may also be initiated in patients within 2 years after myocardial infarction or within 1 year of discontinuing a previous ADP receptor inhibitor (ticlopidine, clopidogrel, prasugrel). - The safety and efficacy of this medicine were evaluated at 3 years of follow-up. Patients with type 2 diabetes who have undergone percutaneous coronary intervention (PCI) for coronary artery disease: Administer 60mg twice daily. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 150mg), unless specifically contraindicated. - For patients with acute coronary syndrome, refer to the relevant dosage and administration instructions. - Data on the safety and efficacy of this medicine when administered for more than 3 years are limited. Patients with acute ischemic stroke or high-risk transient ischemic attack: Administer an initial dose of 180mg, followed by 90mg twice daily for 30 days. Patients taking this medicine should also receive a maintenance dose of aspirin (75 - 100mg), unless specifically contraindicated. An initial loading dose of aspirin (300-325mg) is recommended for patients with acute ischemic stroke or high-risk transient ischemic attack. This medicine is administered orally and may be taken with or without food. For patients who have difficulty swallowing tablets, crush this medicine into a fine powder, disperse it in half a glass of water, and drink it. Rinse the cup used with another half glass of water and drink that as well. This mixture may also be administered through a nasogastric tube (CH8 or larger); it is important to flush the tube with water after administration. If switching to this medicine from another antiplatelet agent, start this medicine 24 hours after the last dose of the previous medicine. If a dose is missed, take only 1 tablet (the next scheduled dose) at the next scheduled dosing time. No dose adjustment is necessary in patients with renal impairment. No dose adjustment is necessary in patients with mild hepatic impairment. This medicine has not been studied in patients with severe hepatic impairment, and experience in patients with moderate hepatic impairment is limited.

Child dose

Safety and efficacy have not been established in pediatric patients under 18 years of age (see the “Other” section).

This medication helps to reduce the risk of cardiovascular events such as myocardial infarction or stroke by preventing platelets in the blood from clumping together to form clots. However, this medication may increase the risk of bleeding and should not be administered to patients with active pathological bleeding or a history of intracranial hemorrhage. Patients scheduled for surgery should discontinue this medication at least 5 days prior to the procedure and consult their healthcare provider to reduce post-surgical bleeding risk. During treatment with this medication, patients should be closely monitored for sudden symptoms of hypotension or signs of bleeding, and should immediately notify a healthcare provider if bleeding is suspected. Particularly high-risk patients or those with severe liver impairment, as well as patients taking certain medications (strong CYP3A4 inhibitors) should not use this medication, and potential interactions with other drugs need to be confirmed. This medication can cause various adverse reactions including dyspnea, bradycardia, and bleeding, so if these symptoms occur, immediate consultation with a healthcare provider is necessary. Women who are pregnant or breastfeeding should consult a physician before taking this medication, as it may pose risks to the fetus or newborn. This medication is not recommended for children and adolescents under 18 years of age, as safety and efficacy have not been established. In cases of overdose, the risk of bleeding may increase, and since there is no specific antidote, appropriate medical treatment should be sought immediately. While taking this medication, patients should be aware that symptoms such as dizziness or confusion may occur during driving or operating machinery.

• Hemorrhage
• intracranial hemorrhage
• ocular hemorrhage
• ear hemorrhage
• hypotension
• dyspnea
• respiratory tract hemorrhage
• gastrointestinal tract hemorrhage
• diarrhea
• nausea

This medication should be kept in a tightly closed container to prevent exposure to air, and it is advisable to store it at room temperature between 1 and 30 degrees Celsius. Proper storage can help maintain the drug's effectiveness for a longer period.

Appearance

Yellow, convex on both sides, circular film-coated tablet

Package unit

56 tablets/box [14 tablets/PTP×4], 30 tablets/box [10 tablets/PTP×3]